Investing.com - Boston Scientific (NYSE: BSX) reported second quarter EPS of $0.62, $0.04 better than the analyst estimate of $0.58. Revenue for the quarter came in at $4.12B versus the consensus estimate of $4.02B.
Guidance
Boston Scientific sees Q3 2024 EPS of $0.57-$0.59 versus the analyst consensus of $0.57.
Boston Scientific sees FY 2024 EPS of $2.38-$2.42 versus the analyst consensus of $2.33.
Boston Scientific's stock price closed at $78.59. It is up 7.41% in the last 3 months and up 49.95% in the last 12 months.
Boston Scientific saw 21 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Boston Scientific's stock price’s past reactions to earnings here.
According to InvestingPro, Boston Scientific's Financial Health score is "great performance".
Check out Boston Scientific's recent earnings performance, and Boston Scientific's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar